![SK Bioscience, a vaccine development and production company, was newly listed on the stock market on the 18th. [사진 출처 = 한국거래소]](https://i0.wp.com/file.mk.co.kr/meet/neds/2021/03/image_readtop_2021_272489_16164139424582652.jpg?w=560&ssl=1)
SK Bioscience, a vaccine development and production company, was newly listed on the stock market on the 18th. [사진 출처 = 한국거래소]SK Bioscience, which has entered the stock market brilliantly while breaking the record of the highest subscription ever, is struggling. It succeeded in’Tasang’ (the upper limit on the first day of listing after the initial price was decided at twice the public offering price), but soon fell by 150,000 won as the stock price fell. Foreigners and institutional investors are joining forces to pour out sales, leading the stock price to decline. On the contrary, the songs of individual investors who rode in anticipation of the’tasangsang’ are increasing day by day.
Selling foreigners and institutions every day… 150,000 won broken
On the 22nd, SK Bioscience closed at 144,000 won, down 13.51% (22,000 won) compared to the previous transaction day. Compared to the public offering price (65,000 won) on this day, it is still more than twice as high, but it is about 15% down from the closing price standard (169,000 won) on the first day of listing.
Earlier, SK Bioscience recorded a competition rate of 1274.47 to 1, with more than 1,000 trillion won in demand forecasting, and 63.619.8 billion won in general public offerings held on the 9th to 10th, recording the largest IPO subscription margin ever. have. Although it was listed amid ever-increasing interest, the stock price flow was unexpected. Foreigners and institutions are behind the sluggish trend. The downward line is collapsing as they sell daily supplies in response to their desire to realize their profits. In addition, the fact that the distribution volume is small is holding back. In general, if the number of shares in circulation immediately after listing is small, it is often beneficial for the stock price to rise. Because the volume is small, it is easy to go straight to the upper limit when buying orders are crowded. SK Bioscience’s initial number of shares in circulation is 8.87 million, 7510 shares, accounting for 11.63% of the total. It is lower than SK Biopharm (13.06%), which recorded the upper limit for 3 consecutive trading days last year, and Kakao Games (20.51%), which recorded’Tasangsang’ (entry to the upper limit for 2 consecutive trading days after 2x the public offering price). However, it became a poison for SK Bioscience and returned. After listing, foreigners and institutions sold 136.3 billion won and 42.9 billion won, respectively. Even on this day, foreigners are maintaining a sell-off of about 29,000 shares. Contrary to expectations, as the stock price did not go out, investors who participated in the public offering stocks are continuing to sell off.
“I’ll hold on to it”
On the other hand, during the same period, individuals are betting on their hopes by making a net purchase of 1976 billion won.
One stock investor said, “While comparing multiple securities companies, I received public offerings while looking forward to getting a lot of money, but I was surprised by the rate of return unexpectedly. I have no choice but to aim for a rebound while waiting for the strong momentum of the novel coronavirus infectious disease (Corona 19) vaccine. “No,” he complained.
Another individual investor said, “The next day, as the purchase volume was released, it went into 180,000 won, but as the price dropped in an instant, I have no choice but to withstand now.” said.
There is even a ridiculous story that the current appearance of SK Bioscience is similar to the trend of last year’s Big Hit. Big Hit, which was listed last year, drew a downward curve for 5 consecutive trading days as foreigners and institutional investors started net selling for 4 consecutive trading days from the date of listing. On the first trading day, the price rose from 351,000 won to 179,000 won, dropping 50%.
A stock market advised that while expressing a positive opinion on the value of SK Bioscience, it should take time for tangible results to come out.
SK Biosciences, K Biosciences, signed a contract with AstraZeneca for the Novavex corona vaccine CMO (consignment production) and CDMO (consignment development production) and a license contract for domestic supply of NovaVax vaccine, and sales are expected to occur in earnest from the second half of this year. Is confirmed. In addition,’NBP 2001′, one of the COVID-19 vaccine candidates under development, is undergoing phase 1 clinical trials since November last year, and GBP510, which is being developed with the support of the Bill Gates Foundation and CEPI, is also undergoing phase 1/2 clinical trials.
Han Byeong-hwa, a researcher at Eugene Investment & Securities, said, “At this point, the success of SK Bioscience’s self-developed vaccine is very important for raising the corporate value.” “It will be possible to grow in corporate value at the level of global new vaccine companies such as Beck, Novavex, and Bioentech.”
Lee Hye-rin, a researcher at KTB Investment & Securities, said, “The performance of new businesses such as the Corona 19 vaccine-related performance to be visible from the second quarter, the clinical results of the developed Corona 19 vaccine pipeline to be confirmed before and after the end of the year, and the CMO business related to the virus carrier after the post-Coona 19 have been listed. It will be a key factor in this,” he analyzed.
[김규리 매경닷컴 기자 [email protected]]
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]